Research programme: muscarinic antagonist/beta-2 agonist therapeutics - GSK/Innoviva

Drug Profile

Research programme: muscarinic antagonist/beta-2 agonist therapeutics - GSK/Innoviva

Alternative Names: GSK-961068; MABA programme - Innoviva; THRX-200495

Latest Information Update: 23 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theravance
  • Developer GlaxoSmithKline; Innoviva
  • Class Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 27 Oct 2011 Preclinical development is ongoing in USA
  • 06 Jul 2007 This programme is still in active development
  • 23 Mar 2005 Theravance's MABA programme has been licensed to GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top